Stryker Co. (NYSE:SYK) Receives $331.52 Average PT from Analysts

Stryker Co. (NYSE:SYKGet Free Report) has earned a consensus rating of “Moderate Buy” from the thirteen analysts that are covering the firm, Marketbeat reports. Three equities research analysts have rated the stock with a hold recommendation and ten have issued a buy recommendation on the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $331.52.

A number of equities research analysts have commented on SYK shares. Citigroup lifted their target price on Stryker from $340.00 to $362.00 and gave the company a “buy” rating in a research report on Wednesday, January 31st. Royal Bank of Canada restated an “outperform” rating and issued a $360.00 target price on shares of Stryker in a research report on Thursday, February 15th. Canaccord Genuity Group upgraded Stryker from a “hold” rating to a “buy” rating and lifted their target price for the company from $315.00 to $360.00 in a research report on Wednesday, January 31st. Canaccord Genuity Group upgraded Stryker from a “hold” rating to a “buy” rating and set a $360.00 target price on the stock in a research report on Wednesday, January 31st. Finally, Wells Fargo & Company lifted their target price on Stryker from $336.00 to $364.00 and gave the company an “overweight” rating in a research report on Wednesday, January 31st.

Get Our Latest Analysis on SYK

Stryker Stock Performance

Shares of Stryker stock opened at $357.87 on Friday. Stryker has a one year low of $249.98 and a one year high of $361.41. The company has a market cap of $136.16 billion, a price-to-earnings ratio of 43.38, a PEG ratio of 2.92 and a beta of 0.89. The company has a debt-to-equity ratio of 0.59, a quick ratio of 0.97 and a current ratio of 1.58. The business’s 50 day moving average price is $345.14 and its 200 day moving average price is $306.45.

Stryker (NYSE:SYKGet Free Report) last announced its quarterly earnings data on Tuesday, January 30th. The medical technology company reported $3.46 EPS for the quarter, topping analysts’ consensus estimates of $3.27 by $0.19. Stryker had a return on equity of 22.99% and a net margin of 15.44%. The firm had revenue of $5.82 billion for the quarter, compared to the consensus estimate of $5.60 billion. During the same quarter last year, the business posted $3.00 earnings per share. The firm’s revenue was up 11.8% compared to the same quarter last year. On average, research analysts predict that Stryker will post 11.86 EPS for the current year.

Stryker Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 30th. Shareholders of record on Friday, March 29th will be given a $0.80 dividend. This represents a $3.20 annualized dividend and a yield of 0.89%. The ex-dividend date of this dividend is Wednesday, March 27th. Stryker’s dividend payout ratio (DPR) is presently 38.79%.

Insider Activity

In other Stryker news, Director Allan C. Golston sold 3,273 shares of the stock in a transaction that occurred on Friday, February 2nd. The stock was sold at an average price of $341.00, for a total transaction of $1,116,093.00. Following the transaction, the director now owns 14,242 shares of the company’s stock, valued at approximately $4,856,522. The transaction was disclosed in a document filed with the SEC, which is available at this link. In other Stryker news, CAO William E. Berry, Jr. sold 7,690 shares of the business’s stock in a transaction on Thursday, March 7th. The stock was sold at an average price of $358.48, for a total transaction of $2,756,711.20. Following the completion of the transaction, the chief accounting officer now owns 3,675 shares in the company, valued at approximately $1,317,414. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Allan C. Golston sold 3,273 shares of the company’s stock in a transaction on Friday, February 2nd. The shares were sold at an average price of $341.00, for a total value of $1,116,093.00. Following the completion of the sale, the director now owns 14,242 shares of the company’s stock, valued at approximately $4,856,522. The disclosure for this sale can be found here. Insiders sold 212,109 shares of company stock worth $72,845,768 over the last ninety days. Corporate insiders own 5.90% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the business. Faithward Advisors LLC raised its stake in shares of Stryker by 3.1% in the 4th quarter. Faithward Advisors LLC now owns 973 shares of the medical technology company’s stock valued at $291,000 after purchasing an additional 29 shares during the period. Bremer Bank National Association raised its stake in shares of Stryker by 4.0% in the 4th quarter. Bremer Bank National Association now owns 888 shares of the medical technology company’s stock valued at $266,000 after purchasing an additional 34 shares during the period. Simon Quick Advisors LLC raised its stake in shares of Stryker by 3.0% in the 4th quarter. Simon Quick Advisors LLC now owns 1,158 shares of the medical technology company’s stock valued at $347,000 after purchasing an additional 34 shares during the period. Consolidated Portfolio Review Corp raised its stake in shares of Stryker by 3.6% in the 4th quarter. Consolidated Portfolio Review Corp now owns 983 shares of the medical technology company’s stock valued at $294,000 after purchasing an additional 34 shares during the period. Finally, FourThought Financial Partners LLC raised its stake in shares of Stryker by 3.3% in the 4th quarter. FourThought Financial Partners LLC now owns 1,076 shares of the medical technology company’s stock valued at $322,000 after purchasing an additional 34 shares during the period. 77.09% of the stock is owned by institutional investors and hedge funds.

Stryker Company Profile

(Get Free Report

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.

See Also

Analyst Recommendations for Stryker (NYSE:SYK)

Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.